Timor-Leste's immunization journey: progress, challenges, and the road to IA2030 a viewpoint on leaving no child...

Timor-Leste, a post-conflict nation with a population of 1.34 million, has steadily developed its immunization program since 2000. This viewpoint analyzes progress toward the Immunization Agenda 2030 (IA2030) goals, identifies persistent surveillance gaps, and extracts lessons for other low-and middle-income countries.

We synthesized data from Timor-Leste's 2023 and 2024 EPI fact sheets, the July 2024 HPV vaccine launch report, WHO surveillance guidance, and IA2030 monitoring frameworks. Coverage trends (2014-2023) and surveillance indicators were evaluated against global standards.

Zero-dose children reduced by 22% in one year (from 4,184 to 3,254). Districts with high dropout rates (DTP1 to DTP3) fell from 36% to 0%. Government financing for vaccines increased from 64% to 80% (2022-2023). However, MCV1 coverage stagnated at 72% (far below the 95% measles elimination threshold). The non-polio AFP rate (0.42/100,000) remains well below the global target of ≥2.0. Only 38% of IgM results returned within 4 days. HPV vaccine launched in July 2024, targeting 11-14-year-old girls.

Timor-Leste demonstrates that political commitment and targeted equity strategies can reduce zero-dose children even in resource-constrained settings. However, surveillance system gaps, particularly for AFP and laboratory turnaround times, pose serious risks for polio eradication and outbreak detection. Key lessons for IA2030 implementation include the following: (1) political stability enables cumulative health system gains; (2) one-year indicator improvements require multi-year validation; (3) surveillance quality determines outbreak response speed; and (4) school-based platforms effectively reach adolescents.